| Luke Nathaniel Andera, MD | |
|
200 1st St Sw, Rochester, MN 55905-9800 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Luke Nathaniel Andera |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 10 Years |
| Location | 200 1st St Sw, Rochester, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790105997 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 66025 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Health System-franciscan Medical Center Inc | La crosse, WI | Hospital |
| Mayo Clinic Hlth Systm Franciscan Hlthcare Sparta | Sparta, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic Health System-franciscan Medical Center Inc | 0345152443 | 419 |
News Archive
Advances in Neonatal Care, the leading source of professional information for neonatal nursing professionals, announced today that its content and CE opportunities are available on the iPad.
Survival rates for cancer patients may be improved by treatment in specialised cancer centers, according to Cochrane researchers. In a review of recent studies, they found that women diagnosed with gynaecological cancer lived longer when treated in specialist compared to non-specialist units.
Salix Pharmaceuticals, Ltd. today announced that the Company has acquired rights to Lumacan™ from Photocure, a Norwegian specialty pharmaceutical company. Lumacan is a novel agent designed to assist in the detection of precancerous and cancerous lesions in the colon.
Spanish and Danish researchers have developed a method for the in vivo study of the unknown metabolism of selenium, an essential element for living beings. The technique can help clarify whether or not it possesses the anti-tumour properties that have been attributed to it and yet have not been verified through clinical trials.
An FDA-approved drug for high blood pressure, guanabenz, prevents myelin loss and alleviates clinical symptoms of multiple sclerosis (MS) in animal models, according to a new study.
› Verified 2 days ago
| Entity Name | Mayo Clinic Health System-franciscan Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629056049 PECOS PAC ID: 0345152443 Enrollment ID: O20031110000684 |
News Archive
Advances in Neonatal Care, the leading source of professional information for neonatal nursing professionals, announced today that its content and CE opportunities are available on the iPad.
Survival rates for cancer patients may be improved by treatment in specialised cancer centers, according to Cochrane researchers. In a review of recent studies, they found that women diagnosed with gynaecological cancer lived longer when treated in specialist compared to non-specialist units.
Salix Pharmaceuticals, Ltd. today announced that the Company has acquired rights to Lumacan™ from Photocure, a Norwegian specialty pharmaceutical company. Lumacan is a novel agent designed to assist in the detection of precancerous and cancerous lesions in the colon.
Spanish and Danish researchers have developed a method for the in vivo study of the unknown metabolism of selenium, an essential element for living beings. The technique can help clarify whether or not it possesses the anti-tumour properties that have been attributed to it and yet have not been verified through clinical trials.
An FDA-approved drug for high blood pressure, guanabenz, prevents myelin loss and alleviates clinical symptoms of multiple sclerosis (MS) in animal models, according to a new study.
› Verified 2 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235588831 PECOS PAC ID: 4385553627 Enrollment ID: O20161109002075 |
News Archive
Advances in Neonatal Care, the leading source of professional information for neonatal nursing professionals, announced today that its content and CE opportunities are available on the iPad.
Survival rates for cancer patients may be improved by treatment in specialised cancer centers, according to Cochrane researchers. In a review of recent studies, they found that women diagnosed with gynaecological cancer lived longer when treated in specialist compared to non-specialist units.
Salix Pharmaceuticals, Ltd. today announced that the Company has acquired rights to Lumacan™ from Photocure, a Norwegian specialty pharmaceutical company. Lumacan is a novel agent designed to assist in the detection of precancerous and cancerous lesions in the colon.
Spanish and Danish researchers have developed a method for the in vivo study of the unknown metabolism of selenium, an essential element for living beings. The technique can help clarify whether or not it possesses the anti-tumour properties that have been attributed to it and yet have not been verified through clinical trials.
An FDA-approved drug for high blood pressure, guanabenz, prevents myelin loss and alleviates clinical symptoms of multiple sclerosis (MS) in animal models, according to a new study.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Luke Nathaniel Andera, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Luke Nathaniel Andera, MD 200 1st St Sw, Rochester, MN 55905-9800 Ph: (507) 284-2511 |
News Archive
Advances in Neonatal Care, the leading source of professional information for neonatal nursing professionals, announced today that its content and CE opportunities are available on the iPad.
Survival rates for cancer patients may be improved by treatment in specialised cancer centers, according to Cochrane researchers. In a review of recent studies, they found that women diagnosed with gynaecological cancer lived longer when treated in specialist compared to non-specialist units.
Salix Pharmaceuticals, Ltd. today announced that the Company has acquired rights to Lumacan™ from Photocure, a Norwegian specialty pharmaceutical company. Lumacan is a novel agent designed to assist in the detection of precancerous and cancerous lesions in the colon.
Spanish and Danish researchers have developed a method for the in vivo study of the unknown metabolism of selenium, an essential element for living beings. The technique can help clarify whether or not it possesses the anti-tumour properties that have been attributed to it and yet have not been verified through clinical trials.
An FDA-approved drug for high blood pressure, guanabenz, prevents myelin loss and alleviates clinical symptoms of multiple sclerosis (MS) in animal models, according to a new study.
› Verified 2 days ago
Dr. Kendall Krystyna Tasche, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Charles Wayne Beatty, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Jan L Kasperbauer, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Nicolas Ernest Maragos, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Laura J Orvidas, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Nicholas Reed Randall, MD Otolaryngology Medicare: May Accept Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Lazaro Rafael Peraza, MD Otolaryngology Medicare: May Accept Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |